The Beacon

H. Jack West, MD
  • 0.0 (0)
  • MEDICINE

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

  1. 08/03/2019

    Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

    Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-responding patients with advanced NSCLC, weighing efficacy, potential toxicity, and cost concerns.

    21 min

  2. 05/03/2019

    Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)

    Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasingly complex patient care, along with the possible future role of artificial intelligence and telemedicine.

    25 min

  3. 28/12/2018

    Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

    Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.

    14 min

  4. 21/12/2018

    What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

    Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer.

    9 min

  5. 11/12/2018

    The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

    Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting.

    10 min

  6. 09/12/2018

    Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

    Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice.

    10 min

  7. 04/12/2018

    The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

    Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and where these results fit into management of patients in this setting.

    7 min

  8. 02/12/2018

    The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

    Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC.

    10 min
See All (74)

About

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Information

  • Creator
    H. Jack West, MD
  • Years Active
    2017 - 2019
  • Episodes
    74
  • Rating
    Clean
  • Copyright
    Copyright © 2021 H. Jack West – All Rights Reserved
  • Show Website
    The Beacon